Article
Become a Member to Save
The International Society for Heart and Lung Transplantation (ISHLT) Congress 2024 Highlights
Summary of the highlights from the ISHLT Annual Meeting 2024; 13-17th April 2024; Prague, Czech Republic, selected by Ms Haifa Lyster, PhD and Dr Jasvir Parmar, BM PhD FRCP FFICM.
Ms Haifa Lyster, Consultant Pharmacist - Transplantation & VADs at Royal Brompton & Harefield Hospitals, and Dr Jasvir Parmar, Consultant Transplant Respiratory Physician at Royal Papworth Hospital, will be discussing their selected topics from the ISHLT 2024 Congress and how these topics may impact current practice in the UK.
Topics chosen:
Immunosenescence, telomere dysfunction and epigenetics: Molecular impact on aging and transplant outcomes.
The use of glucagon-like peptide-1 agonists in ventricular assist devices and transplant patients.
Immunomodulation of the human donor lung ex -vivo with CRISP-mediated activation of IL-10 expression.
Multicenter open-label trial of tacrolimus inhalation powder in lung transplant recipients with renal impairment.
Anti-reflux surgery for prevention of CLAD onset after lung transplantation.
A prospective randomized controlled trial of direct oral anticoagulant therapy with a fully magnetically levitated LVAD: The DOT-HM3 Study.
The content of the ISHLT 2024 is created independently of Takeda.
References:
1. Snyder M. et al., Immunosenescence, Telomere Dysfunction, and Epigenetics in Aging: Effects on Transplant. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
2. Greenland J. Symposium 11: The Molecular Underpinnings of Frailty in Transplant Candidates and Recipients. Presented at the ISHLT 2024 Annual Meeting, 10-13th April 2024; Prague, Czech Republic.
3. Shtraichman O. Symposium 11: Heaven Can Wait: Evaluation of Older Cardiothoracic Transplant Candidates. Presented at the ISHLT 2024 Annual Meeting, 10-13th April 2024; Prague, Czech Republic.
4. inger L. Symposium 11: Quality of Life Following Cardiothoracic Transplantation: Does Recipient Age Matter? Presented at the ISHLT 2024 Annual Meeting, 10-13th April 2024; Prague, Czech Republic.
5. Edwards M. et al., Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
6. Jeyakumar S. et al., Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
7. Mesaki K. et al., CRISPR-Cas Genome Editing in Ex Vivo Human Lungs. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
8. Snell G. et al., Multicenter Open-Label Tacrolimus Inhalation Powder Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics (pk) in Lung Transplant (ltx) Recipients with Significant Renal Impairment. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
9. Hamid A. et al., Anti-Reflux Surgery for Prevention of CLAD Onset After Lung Transplantation: The Earlier the Better? A Single-Center Series of 284 Patients. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
10. Netuka I. et al., Featured Late Breaking Abstract Presentation: A Prospective Randomized Controlled Trial of Direct Oral Anticoagulant Therapy with a Fully Magnetically Levitated LVAD: The DOT-HM3 Study. Presented at ISHLT 2024 Annual Meeting, April 10-13th April, Prague, Czech Republic.
